Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2019’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)

– The report reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chronic Kidney Disease (Chronic Renal Failure) therapeutics and enlists all their major and minor projects

– The report assesses Chronic Kidney Disease (Chronic Renal Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Algernon Pharmaceuticals Inc

Algomedix Inc

Allena Pharmaceuticals Inc

Angion Biomedica Corp

apceth Biopharma GmbH

Arch Biopartners Inc

Aronora Inc

AstraZeneca Plc

Bayer AG

BioAegis Therapeutics Inc

Boehringer Ingelheim International GmbH

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Cellmid Ltd

Cinkate Corp

Corvidia Therapeutics Inc

DiaMedica Therapeutics Inc

Dimerix Ltd

Dizal (Jiangsu) Pharmaceutical Co Ltd

DJS Antibodies Ltd

DURECT Corp

Ember Therapeutics Inc (Inactive)

Evotec SE

G3 Pharmaceuticals Inc

GNI Group Ltd

Indalo Therapeutics Inc

Kaleido Biosciences Inc

KBP BioSciences Co Ltd

KidneyCure Ltd

Kintai Therapeutics Inc

Klotho Therapeutics Inc

Liminal BioSciences Inc

Merck & Co Inc

Novartis AG

OPKO Health Inc

Opsidio LLC

OrthoTrophix Inc

ProKidney LLC

Reata Pharmaceuticals Inc

Redx Pharma Plc

Renibus Therapeutics Inc

Resverlogix Corp

Sarfez Pharmaceuticals Inc

Scohia Pharma Inc

Sentien Biotechnologies Inc

Sphaera Pharma Pte Ltd

Theravance Biopharma Inc

Unicocell Biomed Co Ltd

Unity Biotechnology Inc

Vascular BioSciences

VESSL Therapeutics Ltd

Vidasym Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Chronic Kidney Disease (Chronic Renal Failure) - Overview 6

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development 7

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 17

Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 27

Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles 45

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 199

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 202

Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 203

Appendix 215

List of Tables

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Algernon Pharmaceuticals Inc, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Algomedix Inc, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Allena Pharmaceuticals Inc, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Angion Biomedica Corp, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by apceth Biopharma GmbH, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Arch Biopartners Inc, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Aronora Inc, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by AstraZeneca Plc, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Bayer AG, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by BioAegis Therapeutics Inc, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects, H2 2019 (Contd..1), H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects, H2 2019 (Contd..2), H2 2019

Chronic Kidney Disease (Chronic Renal Failure) – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports